An Investigative Report on the Therapeutic Candidate FAB 117-HC

1. Introduction to FAB 117-HC

1.1. Overview and Initial Identification

FAB 117-HC is an investigational drug candidate that has emerged in recent research literature. However, a comprehensive review of available information reveals a complex and, at times, contradictory profile for this designation. The primary challenge in characterizing FAB 117-HC lies in its association with two distinct therapeutic modalities targeting different medical conditions.

A significant body of evidence points to FAB 117-HC as an advanced cell-based therapy primarily under investigation for the treatment of acute traumatic spinal cord injury.[1] This profile is supported by details regarding its active pharmaceutical ingredient, HC016, its originators, Ferrer Advanced Biotherapeutics and Histocell, and specific clinical trial identifiers (EudraCT 2015-005717-80 and NCT02917291).

Conversely, other sources describe FAB 117-HC, also identified by the alternative name NeuroSave, as a recombinant chimeric monoclonal antibody engineered for the treatment of acute ischemic stroke.[5] This profile outlines a mechanism involving the neutralization of human tissue factor.

The existence of these two fundamentally different therapeutic entities under the same primary designation, "FAB 117-HC," and sharing the alias "NeuroSave" [2], presents a critical discrepancy. This report will systematically delineate both profiles based on the available data, analyze these contradictions, and discuss potential interpretations, particularly concerning the "HC" suffix. The preponderance of detailed information relates to the cell therapy candidate for spinal cord injury, which will consequently receive more extensive coverage.

1.2. Significance of the "HC" Designation – Preliminary Assessment